1. Alvero AB, O’Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G (2006) Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106: 599–608
2. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603–4609
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843–1849
4. Bolanos M, Borrega P, Gonzalez-Beca R, Arranz JA, Velasco A, Perez MM, Gomez-Bernal A, Martinez-Prado P, Pedro de Alcantara HS (2001) Weekly paclitaxel/carboplatinum as first-line chemotherapy in late relapses of epithelial ovarian cancer. A preliminary report on side effects. Proc Am Soc Clin Oncol 20, (abstr 870)
5. Cadron I, Leunen K, Amant F, Van Gorp T, Neven P, Vergote I (2007) The ‘Leuven’ dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 106: 354–361